We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
Robust financial performance driven by full year 2024 royalty revenue growth of 28%Reiterating 2025 financial guidance of $180-$200 million in ...
Eli Lilly said it plans to build three new plants in the U.S. to make the key ingredients used in pharmaceuticals, part of a ...
The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive ...
Eli Lilly plans to invest at least $27 billion to build four new manufacturing sites in the U.S., a week after President Trump reportedly said he planned to impose tariffs of 25% or more on ...
Hikma Pharmaceuticals PLC posted robust financial results for 2024, with revenue climbing 9% to $3.127 billion compared to $2.875 billion in 2023, according to audited figures released Wednesday. The ...
Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...